Billions saved because FDA didn’t rush approval of Alzheimer’s drug

Reuters, 10 May 2017
Author: Gene Emery
“The U.S. Food and Drug Administration’s decision not to rush approval for Eli Lilly’s experimental Alzheimer’s treatment solanezumab – a drug that turned out to be ineffective – may have saved American taxpayers as much as $100 billion over the past four years, an analysis concludes. The analysis comes amid pressure on FDA to use less-strict standards in deciding whether a drug should be approved. Some agency critics have called on the government to approve all drugs that are not toxic and let market forces determine which are best.”
Find article here.